V. Alberola Candel

Phase II trial of oxaliplatin and capecitabine after progression to first-line chemotherapy in androgen-independent prostate cancer patients.

Introduction:Docetaxel plus prednisone is the current standard of care in first-line chemotherapy for metastatic hormone-refractory prostate cancer. However, there is no agent proven as effective after progression to standard docetaxel-based therapy. Platins and capecitabine have shown activity in this setting. Patients and Methods:A total of 14 patients were included in this prospective, single-center trial. All patients had progressed to first-line docetaxel-based treatment. Patients received oxaliplatin 100 mg/sqm on D1 and capecitabine 1000 mg/sqm/bid on days 1 to 14 every 21 days. Results:Median number of cycles was 3. No unexpected toxicity was observed. Only grade 3 toxicity reported was grade 3 anemia. Of the 14 patients, 3 presented grade 2 neuropathy which was spontaneously resolved. Prostate-specific antigenresponse rate was 57%, with a median time to progression of 14.5 weeks, and overall survival of 24 weeks. Conclusions:In the second-line setting, after receiving docetaxel-based chemotherapy, the combination of oxaliplatin and capecitabine offers promising activity with an excellent safety profile.

Experience with fulvestrant acetate in castration-resistant prostate cancer patients

Fulvestrant is a selective estrogen receptor (ER) downregulator; fulvestrant inhibits ER dimerization [1] and reduces ER’s half-life [2]. In preclinical models, fulvestrant inhibited cell growth of the DU145 prostate cancer (PCa) cell line through an ER-b-dependent mechanism [3]. Metastatic PCa expresses ER-b mainly in metastases to the lymph nodes and bones [4]. Androgen receptor (AR) expression is retained in a significant proportion of castration-resistant prostate cancer (CRPC) [5]. Bhattacharyya treated PCa cell lines with fulvestrant obtaining a 70% of inhibition of the cell growth, demonstrating that fulvestrant is a potent AR down-regulator [6]; thus, combined down-regulation of ARs and ERs appears as an attractive strategy for treating CRPC.

Experience with a 22 molecular marker predesigned tissue microarray in the preoperative setting of breast cancer treated with FEC-docetaxel, comparing complete responders with incomplete responders, and incomplete responders before and after treatment

22151 Background: Studies with Tissue Microarray (TMA) technology in the preoperative setting of breast cancer have been done using thousands of genes, searching for the most relevant genes associa...